A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 701–800 of 1,018
A Refined Developability Classification System
Rosenberger, J., Butler, J., & Dressman, J. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.030 · Cited by 92
On the Heterogeneity of Drug Dissolution and Release
Macheras, P. E., & Dokoumetzidis, A. (2000) · Pharmaceutical Research · doi:10.1023/a:1007596709657 · Cited by 105
Multicomponent Amorphous Nanofibers Electrospun from Hot Aqueous Solutions of a Poorly Soluble Drug
Yu, D., Gao, L., White, K., Branford‐White, C., Lu, W., & Zhu, L. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0239-y · Cited by 90
“Although in the past few years formulating poorly water-soluble compounds using a nanoparticle approach has been attempted, there is a growing need for more effective and versatile ways to handle formulation issues associated with poorly watersoluble molecules (13, 14 ).”
BackgroundTsinman, K., Avdeef, A., Tsinman, O., & Voloboy, D. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9921-3 · Cited by 90
A Modern View of Excipient Effects on Bioequivalence: Case Study of Sorbitol
Chen, M.-L., Straughn, A. B., Sadrieh, N. K., Meyer, M., Faustino, P. J., Ciavarella, A. B., Meibohm, B., Yates, C. R., & Hussain, A. S. M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9120-4 · Cited by 91
“the rate and extent of absorption (1).”
Bard, B., Martel, S., & Carrupt, P. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.12.002 · Cited by 90
“…solubility values are also more and more equired in the early discovery to predict qualitatively ioavailability and absorption of orally administered drugs in ccordance with the Biopharmaceutics Classification System” BCS) (Amidon et al., 1995; van de Waterbeemd, 1998; Wei nd Löbenberg, 2006).”
Improving Lithium Therapeutics by Crystal Engineering of Novel Ionic Cocrystals
Smith, A. J., Kim, S.-H., Duggirala, N. K., Jin, J., Wojtas, Ł., Ehrhart, J. C., Giunta, B. N., Tan, J., Zaworotko, M. J., & Shytle, R. D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400571a · Cited by 97
“Furthermore, this is the fi rst report of the pharmacokinetics of a cocrystal of a suspected BCS class I API as de fi ned by Amidon et al. 65 Compared to an FDA-approved lithium salt, lithium carbonate (Li 2 CO 3 ) , in addition to being more e ffi cacious by exploiting potential synergies, LISPRO may also o ff er a better…”
Paxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 96
“Based on these properties Amidon et al. proposed biopharmaceutic classification system (BCS), which in present times is serving as a guide for regulatory and industrial purposes (Amidon et al. 1995).”
Ferraz, R., Silva, D., Dias, A. R., Dias, V., Santos, M. M., Pinheiro, L., Prudêncio, C., Noronha, J. P., Petrovski, Ž., & Branco, L. C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030221 · Cited by 89
Adsorption of meloxicam on porous calcium silicate: Characterization and tablet formulation
Sharma, S., Sher, P., Badve, S. S., & Pawar, A. (2005) · AAPS PharmSciTech · doi:10.1208/pt060476 · Cited by 89
“Most of the antiinflammatory drugs come under class II (drugs with low solubility and high permeability) according to the biopharmaceutical classification system.(1) For most orally administered poorly water soluble compounds, the bio-absorption is rate limited by dissolution.”
BackgroundMolecular Mobility as an Effective Predictor of the Physical Stability of Amorphous Trehalose
Bhardwaj, S. P., & Suryanarayanan, R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300302g · Cited by 89
The BCS: Where Do We Go from Here?
Dressman, J., Butler, J., Hempenstall, J., & Reppas, C. I. (2001) · Pharmaceutical technology · Cited by 89
BDDCS Class Prediction for New Molecular Entities
Broccatelli, F., Cruciani, G., Benet, L. Z., & Oprea, T. I. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2004302 · Cited by 98
Almatroudi, A., Allemailem, K. S., Alwanian, W. M., Alharbi, B. F., Alrumaihi, F., Khan, A. A., Almatroodi, S. A., & Rahmani, A. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108630 · Cited by 99
Tannergren, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00238-8 · Cited by 89
“In contrast to other perfusion systems, with less welldescribed hydrodynamics,7,8 the technique used in this study enables direct determination of the effective jejunal permeability of drugs.9 This transport parameter is a part of the Biopharmaceutics Classification System.10 The histamine H1 receptor antagonist fexof…”
BackgroundMohd, A. B., Sanka, K., Bandi, S., Diwan, P. V., & Shastri, N. R. (2014) · Drug Delivery · doi:10.3109/10717544.2013.879753 · Cited by 89
“It is likely to show low and irregular bioavailability following oral administration due to the low water solubility (Amidon et al., 1995; Grunenberg et al., 1995).”
BackgroundInfluentialMaeno, Y., Fukami, T., Kawahata, M., Yamaguchi, K., Tagami, T., Ozeki, T., Suzuki, T., & Tomono, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.07.008 · Cited by 88
“Paracetamol (acetyl-para-aminophenol, APAP) is a widely used antipyretic agent and is classified as a class III (high solubility, low permeability) compound in the biopharmaceutics classification system (BCS) (Amidon et al., 1995; Kalantzi et al., 2006).”
BackgroundAshiru-Oredope, D. A. I., Patel, R., & Basit, A. W. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9635-y · Cited by 91
“Ranitidine is a class III compound (high solubility, poor permeability) according to the Biopharmaceutics Classification System (BCS) and is mainly absorbed in the small intestine (7).”
BackgroundRecent progress in the computational prediction of aqueous solubility and absorption
Johnson, S. R., & Zheng, W. (2006) · The AAPS Journal · doi:10.1208/aapsj080104 · Cited by 88
Adnet, T., Groo, A., Picard, C., Davis, A., Corvaisier, S., Since, M., Bounoure, F., Rochais, C., Pluart, L. L., Dallemagne, P., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030251 · Cited by 88
“Thus, because of this limited permeability and its good water solubility (>10 mg/mL), the API can be considered as a class III BCS drug [16].”
BackgroundHe, X., Pei, L., Tong, H. H. Y., & Zheng, Y. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9560-3 · Cited by 87
Thomas, N., Müllertz, A., Graf, A., & Rades, T. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23054 · Cited by 92
“The selection of suitable SNEDDS preconcentrates for further studies was based on the following criteria: (1) SNEDDS preconcentrates had to be isotropic liquids at ambient temperature; (2) MC- and LCSNEDDS preconcentrates had to consist of the same ratio of lipid, surfactant, and cosolvent; (3) SNEDDS preconcentrates…”
MethodKortejärvi, H., Urtti, A. O., & Yliperttula, M. L. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.10.011 · Cited by 87
Quantitative structure–pharmacokinetic/pharmacodynamic relationships
Mager, D. E. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.08.002 · Cited by 105
Dahan, A., Beig, A., Ioffe, V., Agbaria, R., & Miller, J. M. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9445-3 · Cited by 90
Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine
Kasten, G., Nouri, K., Grohganz, H., Rades, T., & Löbmann, K. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.063 · Cited by 87
“This is a characteristic of drugs classified as class II or IV in the Biopharmaceutics Classification System (BCS) (Amidon et al., 1995), having solubility as a limiting step for oral absorption and consequently bioavailability (Savjani et al., 2012).”
BackgroundKalivoda, A., Fischbach, M., & Kleinebudde, P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.013 · Cited by 86
Selection of In Vivo Predictive Dissolution Media Using Drug Substance and Physiological Properties
Mudie, D. M., Samiei, N., Marshall, D. J., Amidon, G. E., & Bergström, C. A. S. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0417-8 · Cited by 86
Self-citationWalden, D. M., Bundey, Y., Jagarapu, A., Antontsev, V. G., Chakravarty, K., & Varshney, J. (2021) · Molecules · doi:10.3390/molecules26010182 · Cited by 87
“ity, low permeability) active pharmaceutical ingredients (APIs) [1], including particle size reduction (micronization) [12,13], salt formation and co-crystallization [14,15], lipid-based delivery [16,17], and cyclodextrin complexation [18].”
BackgroundMesoporous Carbon: A Versatile Material for Scientific Applications
Rahman, M. M., Ara, M. G., Alim, M. A., Uddin, M. S., Najda, A., Albadrani, G. M., Sayed, A. A., Mousa, S. A., & Abdel‐Daim, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094498 · Cited by 90
The Influence of Chronic Renal Failure on Drug Metabolism and Transport
DREISBACH, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.163 · Cited by 86
Janssens, S., de Armas, H. N., Remon, J. P., & den Mooter, G. V. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.11.015 · Cited by 104
Modeling Kinetics of Subcellular Disposition of Chemicals
Baláž, Š. (2009) · Chemical Reviews · doi:10.1021/cr030440j · Cited by 98
Development and Validation of a Preclinical Food Effect Model
Lentz, K. A., Quitko, M., Morgan, D. G., Grace, J. E., Gleason, C. R., & Marathe, P. H. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20767 · Cited by 86
Crystal engineering approach to improve the solubility of mebendazole
Chen, J., Wang, Z., Wu, C., Song, L., & Lu, T. (2012) · CrystEngComm · doi:10.1039/c2ce25724f · Cited by 86
Polymer-mediated disruption of drug crystallinity
Rawlinson-Malone, C. F., Williams, A. C., Timmins, P., & Grimsey, I. M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.11.029 · Cited by 86
New Cocrystals of Hydrochlorothiazide: Optimizing Solubility and Membrane Diffusivity
Gopi, S. P., Banik, M., & Desiraju, G. R. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b01540 · Cited by 86
Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development
Lennernäs, H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4003392 · Cited by 92
Self-citationRamírez, E., Laosa, O., Guerra, P., Duque, B., Mosquera, B., Borobia, A. M., Lei, S. H., Carcas, A. J., & Frías, J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03757.x · Cited by 97
Development and characterization of a lovastatin-loaded self-microemulsifying drug delivery system
Singh, S. K., Verma, P. R. P., & Razdan, B. (2009) · Pharmaceutical Development and Technology · doi:10.3109/10837450903286537 · Cited by 92
“Attempts to enhance drug solubility of these therapeutics agents correlate well with enhancement in their bioavailability.([1]) Various formulation strategies are reported in the literature including the use of surfactants, cyclodextrins, nanoparticles, solid dispersions, micronization, lipids and permeation enhancers…”
BackgroundPreparation and in vitro/in vivo evaluation of fenofibrate nanocrystals
Zuo, B., Sun, Y. H., Li, H., Liu, X., Zhai, Y., Sun, J., & He, Z. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.021 · Cited by 85
Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability
Wu, J., Yang, M., van den Berg, F. W. J., Pajander, J. P., Rades, T., & Rantanen, J. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.008 · Cited by 85
Tong, H. H. Y., Du, Z., Wang, G. N., Chan, H., Chang, Q., Lai, L. C. M., Chow, A. H. L., & Zheng, Y. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.11.027 · Cited by 85
Frick, A. D., Möller, H., & Wirbitzki, E. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00041-1 · Cited by 85
Prediction of dissolution–absorption relationships from a dissolution/Caco-2 system
Ginski, M. J. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00330-5 · Cited by 85
Oral delivery system enhanced the bioavailability of stilbenes: Resveratrol and pterostilbene
Peng, R., Lin, G., Ting, Y., & Hu, J. (2018) · BioFactors · doi:10.1002/biof.1405 · Cited by 86
“Thus, even a small increase in the solubility may significantly enhance the bioavailability of such compounds [70].”
BackgroundHuman Primary Cell-Based Organotypic Microtissues for Modeling Small Intestinal Drug Absorption
Ayehunie, S., Landry, T., Stevens, Z., Armento, A., Hayden, P. J., & Klausner, M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2362-0 · Cited by 91
Sánchez‐Marzo, N., Pérez-Sánchez, A., Ruiz-Torres, V., Martínez-Tébar, A., Castillo, J., Herranz‐López, M., & Barrajón‐Catalán, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092148 · Cited by 90
“To avoid this situation, different apigenin salt derivates were obtained, leading to increased solubility [30,34].”
Cirri, M., Mennini, N., Maestrelli, F., Mura, P., Ghelardini, C., & Mannelli, L. D. C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.02.022 · Cited by 90
Abbas, H., Refai, H., & Sayed, N. S. E. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.04.007 · Cited by 88
Ethanol Effects on Apparent Solubility of Poorly Soluble Drugs in Simulated Intestinal Fluid
Fagerberg, J. H., Al-Tikriti, Y., Ragnarsson, G., & Bergström, C. A. S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2006467 · Cited by 84
Onoue, S., Sato, H., Ogawa, K., Kawabata, Y., Mizumoto, T., Yuminoki, K., Hashimoto, N., & Yamada, S. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.007 · Cited by 85
Ogawa, R., Stachnik, J. M., & Echizen, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0189-3 · Cited by 90
“The Biopharmaceutics Classification System (BCS) was developed by Amidon and co-workers for predicting the oral absorption of drugs based upon their water solubility and intestinal permeability [11].”
MethodTanis, I., & Karatasos, K. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9039176 · Cited by 88
Hughey, J. R., DiNunzio, J. C., Bennett, R. C., Brough, C., Miller, D. A., Ma, H., Williams, R. O., & McGinity, J. W. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9431-y · Cited by 84
“classified as a class II drug, ROA exhibits high permeability in the gastrointestinal lumen ( 1 ).”
BackgroundKovarik, J. M., Hartmann, S., Figueiredo, J., Rordorf, C. M., Golor, G., Lison, A. E., Budde, K., & Neumayer, H. H. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.3.154.33542 · Cited by 84
Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier
Mathot, F., Rieux, A. D., Ariën, A., Schneider, Y., Brewster, M. E., & Préat, V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.001 · Cited by 87
“These materials are representative class II (low solubility — high permeability) and IV (low solubility — low permeability) compounds as described by the Biopharmaceutical Classification System (BCS) [46].”
MethodModels to Predict Intestinal Absorption of Therapeutic Peptides and Proteins
Antunes, F., Andrade, F., Ferreira, D., Nielsen, H. M., & Sarmento, B. F. C. C. (2012) · Current Drug Metabolism · doi:10.2174/1389200211309010004 · Cited by 87
Dahan, A., & Amidon, G. L. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9789-7 · Cited by 93
Self-citationZaman, B., Siddique, F., & Hassan, W. (2016) · Chromatographia · doi:10.1007/s10337-016-3179-9 · Cited by 96
“LED belongs to BCS class II and exhibits low pH-dependent solubility and high apparent permeability [19, 20].”
BackgroundJakubowska, E., & Lulek, J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102357 · Cited by 83
Methotrexate: A Gold Standard for Treatment of Rheumatoid Arthritis
Shinde, C. G., Venkatesh, M. P., Kumar, T. M. P., & Shivakumar, H. G. (2014) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2014.959238 · Cited by 83
“[8] Amidon GL, Lennernäs H, Shah VP, Crison JR.”
BackgroundThe Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship
Dahan, A., Lennernäs, H., & Amidon, G. L. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300140h · Cited by 83
Self-citationRiyadi, P. H., Romadhon, R., Sari, I. D., Kurniasih, R. A., Agustini, T. W., Swastawati, F., Herawati, V. E., & Tanod, W. A. (2021) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/890/1/012021 · Cited by 88
Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying
Kumar, S., Gokhale, R. D., & Burgess, D. J. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.060 · Cited by 83
de Waard, H., Hinrichs, W. L. J., Visser, M. R., Bologna, C., & Frijlink, H. W. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.07.023 · Cited by 83
Gershkovich, P., Wasan, E. K., Lin, M., Sivak, O., Leon, C. G., Clement, J. G., & Wasan, K. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp140 · Cited by 81
Veterinary Medicine Needs New Green Antimicrobial Drugs
Toutain, P., Ferran, A. A., Bousquet‐mélou, A., Pelligand, L., & Lees, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01196 · Cited by 88
“On the Biopharmaceutics Classification System (Amidon et al., 1995) drugs are classified as highly or poorly permeable, according to their rate of transit across intestinal cells.”
BackgroundPrice, D. J., Ditzinger, F., Koehl, N. J., Janković, S., Τσακιρίδου, Γ., Nair, A., Holm, R., Kuentz, M., Dressman, J., & Saal, C. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12927 · Cited by 86
“As a result, supersaturating formulations are highly appealing for drugs with low thermodynamic solubility, which often exhibit poor bioavailability.([3]) The gap between the free energy of the supersaturated state and the equilibrium state can lead to stability issues.”
BackgroundSchulze, J. D. R., Waddington, W. A., Ell, P. J., Parsons, G. E., Coffin, M. D., & Basit, A. W. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008046.64409.bd · Cited by 83
“As a small, hydrophilic molecule, ranitidine is believed to be absorbed across the gastrointestinal mucosa via the paracellular route (3) and has been classified as a class III compound (high solubility, low permeability) of the Biopharmaceutics Classification System (4).”
Yang, Y., Manda, P., Pavurala, N., Khan, M. A., & Krishnaiah, Y. S. R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.263 · Cited by 82
Beig, A., Miller, J. M., Lindley, D., Carr, R. A., Zocharski, P., Agbaria, R., & Dahan, A. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24496 · Cited by 82
İnceçayır, T., Tsume, Y., & Amidon, G. L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300410n · Cited by 86
Self-citationStructural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate Phases
Roy, S., Quiñones, R., & Matzger, A. J. (2012) · Crystal Growth & Design · doi:10.1021/cg300152p · Cited by 82
Frank, K. J., Westedt, U., Rosenblatt, K. M., Hölig, P., Rosenberg, J., Mägerlein, M., Brandl, M., & Fricker, G. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.015 · Cited by 88
“Solubility and permeability are key characteristics determining oral bioavailability of drugs (Amidon et al., 1995).”
BackgroundCharacterization of Ternary Solid Dispersions of Itraconazole, PEG 6000, and HPMC 2910 E5
Janssens, S., de Armas, H. N., Roberts, C. J., & den Mooter, G. V. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21128 · Cited by 82
Christophersen, P. C., Christiansen, M. L., Holm, R., Kristensen, J., Jacobsen, J. B., Abrahamsson, B., & Müllertz, A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.007 · Cited by 89
Chaudhari, M. B., Desai, P. P., Patel, P. A., & Patravale, V. B. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0267-6 · Cited by 82
“08 Da) restricting passive diffusion, augmented lipid binding in the gastrointestinal (GI) membrane and extensive P-gp efflux from the enterocytes and its degradation in gastric acidic milieu (pH below 2) [6–8].”
BackgroundZhang, K., Zhang, M., Liu, Z., Zhang, Y., Gu, L., Hu, G., Chen, X., & Jia, J. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.07.008 · Cited by 82
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 82
Grady, H. L., Elder, D. P., Webster, G. K., Mao, Y., Lin, Y., Flanagan, T. R., Mann, J., Blanchard, A., Cohen, M. J., Lin, J., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.10.019 · Cited by 82
Sharifi-Rad, J., Quispe, C., Durazzo, A., Lucarini, M., Souto, E. B., Santini, A., Imran, M., Moussa, A. Y., Mostafa, N. M., El-Shazly, M., et al. (2022) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2022.100550 · Cited by 81
An Updated Review On:Liposomes as Drug Delivery System
Sharma, D., Ali, A. A. E., & Trivedi, L. R. (2018) · Pharmatutor · doi:10.29161/pt.v6.i2.2018.50 · Cited by 81
“(Amidon et al., 1995) Various carriers like nanoparticles, microparticles, polysaccharides, lectins and liposomes can be used to target the drug to a specific site.”
BackgroundZimmermann, A., Millqvist‐Fureby, A., Elema, M. R., HANSEN, T., Müllertz, A., & Hovgaard, L. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.014 · Cited by 81
“Dissolution rate in the gastro-intestinal tract is the rate limiting factor for the absorption of many of these drugs, which therefore suffer from poor oral bioavailability [1].”
BackgroundMethodology of oral formulation selection in the pharmaceutical industry
Kuentz, M., Holm, R., & Elder, D. P. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.008 · Cited by 95
“More recently, biopharmaceutical approaches have proved useful in assessing a candidate's ‘fitness for purpose’ and its ability to deliver adequate exposure (Amidon et al., 1995; Buckley et al., 2013; Butler and Dressman, 2010).”
BackgroundMethodEngineered nanosponges as versatile biodegradable carriers: An insight
Jain, A., Prajapati, S. K., Kumari, A., Mody, N., & Bajpai, M. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101643 · Cited by 90
Production and isolation of pharmaceutical drug nanoparticles
Verma, V., Ryan, K. M., & Padrela, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120708 · Cited by 86
“According to the Biopharmaceutical Classification System (BCS), pharmaceutical drugs are divided into four categories based on their aqueous solubility and intestinal permeability: namely class I (high solubility and high permeability), class II (low solubility and high permeability), class III (high solubility and lo…”
MethodReview of global regulations concerning biowaivers for immediate release solid oral dosage forms
Gupta, E., Barends, D. M., Yamashita, E., Lentz, K. A., Harmsze, A. M., Shah, V. P., Dressman, J., & Lipper, R. A. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.05.001 · Cited by 81
Self-citationWagner, C., Jantratid, E., Kesisoglou, F., Vertzoni, M., Reppas, C. I., & Dressman, J. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.008 · Cited by 88
MCM-41 for furosemide dissolution improvement
Ambrogi, V., Perioli, L., Pagano, C., Latterini, L., Marmottini, F., Ricci, M., & Rossi, C. R. (2011) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2011.07.007 · Cited by 85
Henchoz, Y., Bard, B., Guillarme, D., Carrupt, P., Veuthey, J., & Martel, S. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-2634-y · Cited by 81
Dissolution and Solubility Behavior of Fenofibrate in Sodium Lauryl Sulfate Solutions
Granero, G. E., Ramachandran, C., & Amidon, G. L. (2005) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040500272108 · Cited by 82
Self-citationLennernäs, H., Knutson, L., Knutson, T. W., Hussain, A., Lesko, L. J., Salmonson, T., & Amidon, G. L. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00005-2 · Cited by 87
Self-citationEffect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers
Saha, P., & Kou, J. H. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00089-9 · Cited by 82
Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption
Kaur, N., Narang, A. S., & Bansal, A. K. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.024 · Cited by 86
de Sousa, V., Borges, Simon, Senna, & Cabral (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s39383 · Cited by 76
“Dapsone is a drug with low solubility in water and is categorized as a Class II agent according to the biopharmaceutical classification system proposed by Amidon et al. 4 This characteristic is unfavorable for the production of dapsone formulations with adequate bioavailability.”
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects
Khosravan, R., Grabowski, B. A., Wu, J., Joseph‐Ridge, N., & Vernillet, L. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03016.x · Cited by 80
Mahajan, H. S., & Gattani, S. G. (2009) · Drug Delivery · doi:10.3109/10717540903447194 · Cited by 80
“MET HCl is a class I drug according to the biopharmaceutical classification system (Amidon et al., 1995); the significantly higher bioavailability of its intranasal gel as compared to its oral solution could therefore be attributed avoiding the first pass metabolism associated with peroral drug administration.”
BackgroundRahman, Z., Zidan, A. S., & Khan, M. A. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.025 · Cited by 80
Boateng, J. S., Matthews, K. H., Auffret, A. D., Humphrey, M. J., Stevens, H. N. E., & Eccleston, G. M. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.038 · Cited by 86
“…Boateng et al. / International Jou aracetamol was chosen as a model soluble drug (class I) according o the biopharmaceutics classification system (Amidon et al., 1995). he release characteristics of paracetamol from the wafers and lms were compared to investigate the effects of differences in…”
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.